They demonstrated the binding of streptonigrin to the N-terminus of TGase2 and importantly, a single dose of streptonigrin (0.2 mg/kg, daily × 5 per week, orally) showed marked antitumor effects associated with p53 stabilization in a preclinical RCC tumor model [160]. Here, TP53 is linked to neoplasm.